CN105087470A - 人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 - Google Patents
人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 Download PDFInfo
- Publication number
- CN105087470A CN105087470A CN201510484060.XA CN201510484060A CN105087470A CN 105087470 A CN105087470 A CN 105087470A CN 201510484060 A CN201510484060 A CN 201510484060A CN 105087470 A CN105087470 A CN 105087470A
- Authority
- CN
- China
- Prior art keywords
- cell
- placenta
- stem cells
- mesenchymal stem
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000003169 placental effect Effects 0.000 title claims abstract description 15
- 210000002901 mesenchymal stem cell Anatomy 0.000 title abstract 9
- 210000002993 trophoblast Anatomy 0.000 title abstract 7
- 210000002826 placenta Anatomy 0.000 claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 29
- 230000029087 digestion Effects 0.000 claims abstract description 22
- 210000005059 placental tissue Anatomy 0.000 claims abstract description 12
- 239000006285 cell suspension Substances 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 239000012679 serum free medium Substances 0.000 claims abstract description 5
- 238000012545 processing Methods 0.000 claims abstract description 3
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 210000003716 mesoderm Anatomy 0.000 claims description 31
- 210000001915 nurse cell Anatomy 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- 230000001413 cellular effect Effects 0.000 claims description 12
- 210000001161 mammalian embryo Anatomy 0.000 claims description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 244000309466 calf Species 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 9
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 7
- 230000005486 microgravity Effects 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 6
- 210000002249 digestive system Anatomy 0.000 claims description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims description 6
- 229960001471 sodium selenite Drugs 0.000 claims description 6
- 239000011781 sodium selenite Substances 0.000 claims description 6
- 235000015921 sodium selenite Nutrition 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 230000001464 adherent effect Effects 0.000 claims description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 3
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 3
- 210000001691 amnion Anatomy 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 230000005672 electromagnetic field Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000032696 parturition Effects 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- KQSBZNJFKWOQQK-UHFFFAOYSA-N hystazarin Natural products O=C1C2=CC=CC=C2C(=O)C2=C1C=C(O)C(O)=C2 KQSBZNJFKWOQQK-UHFFFAOYSA-N 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003526 lymphopoietic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
90%Percoll(ml) | D-Hank’s(ml) | Density | Final concentration(%) |
14.4 | 5.6 | 1.0.85 | 65 |
12.2 | 7.8 | 1.072 | 55 |
10.0 | 10.0 | 1.059 | 45 |
7.8 | 12.2 | 1.046 | 35 |
5.6 | 14.4 | 1.033 | 25 |
3.3 | 16.7 | 1.020 | 15 |
1.1 | 18.9 | 1.007 | 5 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510484060.XA CN105087470A (zh) | 2015-07-31 | 2015-07-31 | 人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510484060.XA CN105087470A (zh) | 2015-07-31 | 2015-07-31 | 人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105087470A true CN105087470A (zh) | 2015-11-25 |
Family
ID=54568806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510484060.XA Pending CN105087470A (zh) | 2015-07-31 | 2015-07-31 | 人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105087470A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107083382A (zh) * | 2017-05-25 | 2017-08-22 | 广州奇辉生物科技有限公司 | 一种用于保护游离dna的血液保存剂及其应用 |
CN108611317A (zh) * | 2018-04-25 | 2018-10-02 | 北京市农林科学院 | N-乙酰半胱氨酸用于制备猪胎盘滋养层细胞体外培养剂中的应用 |
CN108998409A (zh) * | 2018-08-09 | 2018-12-14 | 广州杜德生物科技有限公司 | 人胚胎滋养细胞和胎盘间充质干细胞的分离纯化方法 |
CN109459372A (zh) * | 2018-10-29 | 2019-03-12 | 迪瑞医疗科技股份有限公司 | 有核红细胞模拟粒子及其制备方法与应用 |
CN110129256A (zh) * | 2019-06-05 | 2019-08-16 | 中国科学院亚热带农业生态研究所 | 一种猪源3d胎盘类器官模型的建立方法 |
CN113040133A (zh) * | 2021-03-22 | 2021-06-29 | 北京贝来药业有限公司 | 作为干细胞来源的脐带/胎盘组织采集试剂盒及方法 |
-
2015
- 2015-07-31 CN CN201510484060.XA patent/CN105087470A/zh active Pending
Non-Patent Citations (3)
Title |
---|
PAROLINI O等: "Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells", 《STEM CELLS》 * |
沙文琼等: "人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化", 《中国组织工程研究与临床康复》 * |
罗飞等: "模拟微重力环境促进人间充质干细胞体外高效增殖", 《第三军医大学学报》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107083382A (zh) * | 2017-05-25 | 2017-08-22 | 广州奇辉生物科技有限公司 | 一种用于保护游离dna的血液保存剂及其应用 |
CN107083382B (zh) * | 2017-05-25 | 2018-07-31 | 广州奇辉生物科技有限公司 | 一种用于保护游离dna的血液保存剂及其应用 |
CN108611317A (zh) * | 2018-04-25 | 2018-10-02 | 北京市农林科学院 | N-乙酰半胱氨酸用于制备猪胎盘滋养层细胞体外培养剂中的应用 |
CN108998409A (zh) * | 2018-08-09 | 2018-12-14 | 广州杜德生物科技有限公司 | 人胚胎滋养细胞和胎盘间充质干细胞的分离纯化方法 |
CN109459372A (zh) * | 2018-10-29 | 2019-03-12 | 迪瑞医疗科技股份有限公司 | 有核红细胞模拟粒子及其制备方法与应用 |
CN109459372B (zh) * | 2018-10-29 | 2021-03-26 | 迪瑞医疗科技股份有限公司 | 有核红细胞模拟粒子及其制备方法与应用 |
CN110129256A (zh) * | 2019-06-05 | 2019-08-16 | 中国科学院亚热带农业生态研究所 | 一种猪源3d胎盘类器官模型的建立方法 |
CN113040133A (zh) * | 2021-03-22 | 2021-06-29 | 北京贝来药业有限公司 | 作为干细胞来源的脐带/胎盘组织采集试剂盒及方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087470A (zh) | 人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化方法 | |
CN104630144B (zh) | 一种脐血间充质干细胞的分离及培养方法 | |
CN103966162B (zh) | 一种经血来源间充质干细胞分离方法 | |
WO2016049986A1 (zh) | 一种脐带间充质干细胞的分离方法 | |
Yang et al. | Immunohistochemical analysis of human mesenchymal stem cells differentiating into chondrogenic, osteogenic, and adipogenic lineages | |
CN104694471A (zh) | 体外诱导胚胎干细胞分化为红系细胞的方法 | |
CN107254432A (zh) | 一种同时分离尿源性干细胞两种亚群的培养基、分离方法及应用 | |
CN109749993B (zh) | 一种脐带间充质干细胞的培养方法 | |
CN109971709A (zh) | 一种iPS细胞分化制备巨噬细胞的方法 | |
CN103013917A (zh) | 人羊膜间充质干细胞分化为神经元样细胞的诱导方法 | |
WO2009030092A1 (en) | Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof | |
CN107267453A (zh) | 一种用于培养脂肪间充质干细胞的培养基及其应用 | |
CN105532647A (zh) | 经血保存液及其应用、经血源宫内膜干细胞的分离培养方法 | |
CN115873789A (zh) | 人脐带间充质干细胞成脂诱导分化培养基及其应用 | |
CN106011052A (zh) | 一种高纯度经血来源干细胞的制备方法 | |
CN105420185A (zh) | 一种从脐带外层羊膜组织中分离提取hUC-MSC的方法 | |
CN103013912A (zh) | 密度梯度离心法分离培养人骨髓间充质干细胞的方法 | |
CN105062966A (zh) | 一种人胚胎滋养细胞和胎盘间充质干细胞的生产方法 | |
CN105002136A (zh) | 人胎盘间充质干细胞的分离方法 | |
CN113249314B (zh) | 促进间充质干细胞增殖与分化的培养方法及无血清培养基 | |
CN111690686B (zh) | 一种miRNA高表达在促进脐带间充质干细胞体外增殖和成骨分化方面的应用 | |
CN107236705B (zh) | 一种人胎盘绒毛膜间充质干细胞培养体系 | |
CN104830764A (zh) | 羊水间充质干细胞的原代分离培养方法 | |
CN111172104A (zh) | 一种脐血间充质干细胞的分离培养方法 | |
CN108660108A (zh) | 一种可增强脐带间充质干细胞免疫调节能力的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Jun Inventor after: Ma Yuchun Inventor after: Li Zhuo Inventor before: He Jing |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180202 Address after: 116600 Jinma economic and Technological Development Zone, Dalian, Liaoning Province, number 2, No. 23 - Jinma B Applicant after: Dalian Jinma Health Industry Development Co., Ltd. Address before: 250013 the 34 sick area of Qianfo Hill Hospital of Shandong Province, Shandong Province, Ji'nan, Shandong Applicant before: He Jing |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151125 |
|
RJ01 | Rejection of invention patent application after publication |